SA517381261B1 - عملية إنتاج مركبات كازين ثلاثي الحديد n- أسيتيل الأسبرتيل واستخدامها في التركيبات الصيدلانية - Google Patents
عملية إنتاج مركبات كازين ثلاثي الحديد n- أسيتيل الأسبرتيل واستخدامها في التركيبات الصيدلانية Download PDFInfo
- Publication number
- SA517381261B1 SA517381261B1 SA517381261A SA517381261A SA517381261B1 SA 517381261 B1 SA517381261 B1 SA 517381261B1 SA 517381261 A SA517381261 A SA 517381261A SA 517381261 A SA517381261 A SA 517381261A SA 517381261 B1 SA517381261 B1 SA 517381261B1
- Authority
- SA
- Saudi Arabia
- Prior art keywords
- casein
- acetyl
- aspartyl
- aspartylated
- chloride
- Prior art date
Links
- 239000005018 casein Substances 0.000 title claims abstract description 105
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 title claims abstract description 99
- 235000021240 caseins Nutrition 0.000 title claims abstract description 99
- 238000000034 method Methods 0.000 title claims abstract description 27
- 230000008569 process Effects 0.000 title claims abstract description 23
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 7
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 title abstract 3
- 238000006243 chemical reaction Methods 0.000 claims abstract description 19
- 229910021578 Iron(III) chloride Inorganic materials 0.000 claims abstract description 14
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 claims abstract description 14
- 238000002360 preparation method Methods 0.000 claims abstract description 14
- 150000001875 compounds Chemical class 0.000 claims description 18
- -1 N-acetyl L-aspartyl chloride Chemical compound 0.000 claims description 16
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 15
- 235000013305 food Nutrition 0.000 claims description 14
- 238000001035 drying Methods 0.000 claims description 5
- 238000011065 in-situ storage Methods 0.000 claims description 4
- 239000000654 additive Substances 0.000 claims description 2
- 239000012320 chlorinating reagent Substances 0.000 claims description 2
- 239000003755 preservative agent Substances 0.000 claims description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 claims 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 claims 2
- FAIAAWCVCHQXDN-UHFFFAOYSA-N phosphorus trichloride Chemical compound ClP(Cl)Cl FAIAAWCVCHQXDN-UHFFFAOYSA-N 0.000 claims 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 claims 2
- 241000196324 Embryophyta Species 0.000 claims 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 claims 1
- 238000004108 freeze drying Methods 0.000 claims 1
- UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 claims 1
- 239000011814 protection agent Substances 0.000 claims 1
- 238000001694 spray drying Methods 0.000 claims 1
- 206010022971 Iron Deficiencies Diseases 0.000 abstract description 7
- 238000002560 therapeutic procedure Methods 0.000 abstract description 6
- 241001465754 Metazoa Species 0.000 abstract description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 91
- 239000000243 solution Substances 0.000 description 68
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 60
- 229910052742 iron Inorganic materials 0.000 description 47
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 27
- 238000000746 purification Methods 0.000 description 25
- 239000000047 product Substances 0.000 description 19
- 238000003756 stirring Methods 0.000 description 18
- 239000000725 suspension Substances 0.000 description 18
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 18
- 238000001556 precipitation Methods 0.000 description 12
- 239000007795 chemical reaction product Substances 0.000 description 11
- 239000000523 sample Substances 0.000 description 11
- 229910001220 stainless steel Inorganic materials 0.000 description 11
- 239000010935 stainless steel Substances 0.000 description 11
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
- 229960005261 aspartic acid Drugs 0.000 description 9
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 9
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 9
- 238000013467 fragmentation Methods 0.000 description 8
- 238000006062 fragmentation reaction Methods 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 150000003839 salts Chemical class 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 239000000203 mixture Substances 0.000 description 6
- OTCCIMWXFLJLIA-BYPYZUCNSA-N N-acetyl-L-aspartic acid Chemical compound CC(=O)N[C@H](C(O)=O)CC(O)=O OTCCIMWXFLJLIA-BYPYZUCNSA-N 0.000 description 5
- 239000012535 impurity Substances 0.000 description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- 102000014171 Milk Proteins Human genes 0.000 description 4
- 108010011756 Milk Proteins Proteins 0.000 description 4
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 125000004080 3-carboxypropanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C(O[H])=O 0.000 description 3
- CKLJMWTZIZZHCS-UWTATZPHSA-N D-aspartic acid Chemical compound OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 3
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical class [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 229940071162 caseinate Drugs 0.000 description 3
- 238000005660 chlorination reaction Methods 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 239000012456 homogeneous solution Substances 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 150000002505 iron Chemical class 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 235000021239 milk protein Nutrition 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 208000015710 Iron-Deficiency Anemia Diseases 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 229940009098 aspartate Drugs 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 238000004159 blood analysis Methods 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229940121657 clinical drug Drugs 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 230000020477 pH reduction Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 230000000284 resting effect Effects 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 2
- 231100000027 toxicology Toxicity 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- HFYBILGYELUOLJ-REOHCLBHSA-N (2S)-2-aminobutanedioyl dichloride Chemical compound N[C@@H](CC(=O)Cl)C(=O)Cl HFYBILGYELUOLJ-REOHCLBHSA-N 0.000 description 1
- GWKOSRIHVSBBIA-REOHCLBHSA-N (3s)-3-aminooxolane-2,5-dione Chemical compound N[C@H]1CC(=O)OC1=O GWKOSRIHVSBBIA-REOHCLBHSA-N 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- ULOXHJSLEWZRIT-UHFFFAOYSA-N [Fe].C[C]=O Chemical compound [Fe].C[C]=O ULOXHJSLEWZRIT-UHFFFAOYSA-N 0.000 description 1
- 150000001263 acyl chlorides Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 238000003975 animal breeding Methods 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 150000001509 aspartic acid derivatives Chemical class 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000000889 atomisation Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- HRYZWHHZPQKTII-UHFFFAOYSA-N chloroethane Chemical compound CCCl HRYZWHHZPQKTII-UHFFFAOYSA-N 0.000 description 1
- 208000036654 deficiency anemia Diseases 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000005218 dilaceration Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 229960003750 ethyl chloride Drugs 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 235000020243 first infant milk formula Nutrition 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000011902 gastrointestinal surgery Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 230000001057 ionotropic effect Effects 0.000 description 1
- 230000003447 ipsilateral effect Effects 0.000 description 1
- 150000002506 iron compounds Chemical class 0.000 description 1
- 108010084684 iron protein succinylate Proteins 0.000 description 1
- 229940074442 iron protein succinylate Drugs 0.000 description 1
- QDUZQOIJXPPTLY-IYEMJOQQSA-N iron;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoic acid Chemical compound [Fe].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O QDUZQOIJXPPTLY-IYEMJOQQSA-N 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 150000002736 metal compounds Chemical class 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000009145 protein modification Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 230000009919 sequestration Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 238000010613 succinylation reaction Methods 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- OHHPDCXHPJUYIG-UHFFFAOYSA-N sulfur dioxide;hydrochloride Chemical compound Cl.O=S=O OHHPDCXHPJUYIG-UHFFFAOYSA-N 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4732—Casein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14386034.4A EP3034512B1 (en) | 2014-12-19 | 2014-12-19 | A process for producing iron (III) casein N-acetyl-aspartylated complexes and use thereof in pharmaceutical compositions |
| PCT/EP2015/074482 WO2016096203A1 (en) | 2014-12-19 | 2015-10-22 | A process for producing iron (iii) casein n-acetyl-aspartylated complexes and use thereof in pharmaceutical compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SA517381261B1 true SA517381261B1 (ar) | 2017-12-20 |
Family
ID=52354737
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SA517381261A SA517381261B1 (ar) | 2014-12-19 | 2017-04-05 | عملية إنتاج مركبات كازين ثلاثي الحديد n- أسيتيل الأسبرتيل واستخدامها في التركيبات الصيدلانية |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US20170340747A1 (enExample) |
| EP (1) | EP3034512B1 (enExample) |
| AP (1) | AP2017009801A0 (enExample) |
| AU (1) | AU2015365885B2 (enExample) |
| BR (1) | BR112017006621B1 (enExample) |
| CA (1) | CA2959226C (enExample) |
| CL (1) | CL2017001611A1 (enExample) |
| CO (1) | CO2017003313A2 (enExample) |
| CY (1) | CY1120037T1 (enExample) |
| DK (1) | DK3034512T3 (enExample) |
| EA (1) | EA031968B1 (enExample) |
| ES (1) | ES2655238T3 (enExample) |
| GE (2) | GEAP201914514A (enExample) |
| HR (1) | HRP20171965T1 (enExample) |
| HU (1) | HUE035302T2 (enExample) |
| IL (1) | IL251449B (enExample) |
| LT (1) | LT3034512T (enExample) |
| MX (1) | MX374777B (enExample) |
| MY (1) | MY185391A (enExample) |
| NO (1) | NO3034512T3 (enExample) |
| PE (1) | PE20180660A1 (enExample) |
| PH (1) | PH12017500391B1 (enExample) |
| PL (1) | PL3034512T3 (enExample) |
| PT (1) | PT3034512T (enExample) |
| RS (1) | RS56714B1 (enExample) |
| SA (1) | SA517381261B1 (enExample) |
| SG (1) | SG11201702593TA (enExample) |
| SI (1) | SI3034512T1 (enExample) |
| SM (1) | SMT201800008T1 (enExample) |
| WO (1) | WO2016096203A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GR1009589B (el) | 2018-04-05 | 2019-09-11 | Ιουλια Κλεωνος Τσετη | Φαρμακευτικο σκευασμα για την αντιμετωπιση της αναιμιας, σε καταλληλο περιεκτη, που διατηρει στεγανα διαχωρισμενα μεταξυ τους τα δραστικα συστατικα: συμπλοκο του τρισθενους σιδηρου με ν-ακετυλο-l-ασπαρτικη καζεϊνη και πενταϋδρικο φυλλινικο ασβεστιο |
| CN116655512A (zh) * | 2023-05-31 | 2023-08-29 | 江苏阿尔法药业股份有限公司 | 一种卡托普利的制备工艺 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB910321A (en) | 1960-02-25 | 1962-11-14 | Olivier Paul Gaudin | Improvements in and relating to a process for preparing ferrous salts of aspartic acid and medicines containing these salts |
| IT1150213B (it) | 1982-03-02 | 1986-12-10 | Italfarmaco Spa | Derivati di ferro biodisponibile esenti da gastrolesivita',procentimento di preparazione e relative composizioni farmaceutiche |
| IT1207996B (it) | 1986-03-18 | 1989-06-01 | Magis Farmaceutici | Composti contenenti ferro biodisponibile, procedimento per la loro preparazione e composizioni farmaceutiche che li contengono. |
| GB9621273D0 (en) | 1996-10-11 | 1996-11-27 | Cortecs Ltd | Therapeutic method |
| IT1297022B1 (it) | 1997-12-24 | 1999-08-03 | Chemi Spa | Complesso di ferro-succinilcaseina, processo per la sua preparazione e composizioni farmaceutiche che lo contengono |
| ITMO20040200A1 (it) | 2004-07-29 | 2004-10-29 | Biofer Spa | Processo per la produzione di complessi ferro succinilcaseina e ferro casein acetil aspartilato e loro utilizzato nelle relative composizioni farmaceutiche. |
-
2014
- 2014-12-19 NO NO14386034A patent/NO3034512T3/no unknown
- 2014-12-19 SI SI201430535T patent/SI3034512T1/en unknown
- 2014-12-19 LT LTEP14386034.4T patent/LT3034512T/lt unknown
- 2014-12-19 RS RS20171312A patent/RS56714B1/sr unknown
- 2014-12-19 PL PL14386034T patent/PL3034512T3/pl unknown
- 2014-12-19 SM SM20180008T patent/SMT201800008T1/it unknown
- 2014-12-19 HU HUE14386034A patent/HUE035302T2/en unknown
- 2014-12-19 ES ES14386034.4T patent/ES2655238T3/es active Active
- 2014-12-19 PT PT143860344T patent/PT3034512T/pt unknown
- 2014-12-19 EP EP14386034.4A patent/EP3034512B1/en active Active
- 2014-12-19 DK DK14386034.4T patent/DK3034512T3/en active
-
2015
- 2015-10-22 GE GEAP201914514A patent/GEAP201914514A/en unknown
- 2015-10-22 BR BR112017006621-1A patent/BR112017006621B1/pt active IP Right Grant
- 2015-10-22 SG SG11201702593TA patent/SG11201702593TA/en unknown
- 2015-10-22 AP AP2017009801A patent/AP2017009801A0/en unknown
- 2015-10-22 AU AU2015365885A patent/AU2015365885B2/en active Active
- 2015-10-22 GE GEAP201514514A patent/GEP20207081B/en unknown
- 2015-10-22 WO PCT/EP2015/074482 patent/WO2016096203A1/en not_active Ceased
- 2015-10-22 US US15/536,855 patent/US20170340747A1/en not_active Abandoned
- 2015-10-22 PE PE2017000363A patent/PE20180660A1/es unknown
- 2015-10-22 EA EA201790902A patent/EA031968B1/ru unknown
- 2015-10-22 MX MX2017008100A patent/MX374777B/es active IP Right Grant
- 2015-10-22 CA CA2959226A patent/CA2959226C/en active Active
- 2015-10-22 MY MYPI2017701462A patent/MY185391A/en unknown
-
2017
- 2017-03-02 PH PH12017500391A patent/PH12017500391B1/en unknown
- 2017-03-29 IL IL251449A patent/IL251449B/en active IP Right Grant
- 2017-04-05 CO CONC2017/0003313A patent/CO2017003313A2/es unknown
- 2017-04-05 SA SA517381261A patent/SA517381261B1/ar unknown
- 2017-06-19 CL CL2017001611A patent/CL2017001611A1/es unknown
- 2017-12-19 HR HRP20171965TT patent/HRP20171965T1/hr unknown
- 2017-12-21 CY CY20171101341T patent/CY1120037T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH0310659A (ja) | 鉄高含有ヘム鉄及びその製造法 | |
| DK159824B (da) | Analogifremgangsmaade til fremstilling af succinylferroproteiner | |
| JP5459826B2 (ja) | 皮膚線維芽細胞におけるエラスチン産生促進剤及び血管内皮細胞の増殖促進剤 | |
| DK3034512T3 (en) | A process for the preparation of iron (III)-casein-N-acetyl-aspartylated complexes and their use in pharmaceutical compositions | |
| KR100563361B1 (ko) | 페로-숙신일카제인 착화물, 그 제조방법 및 이를 함유하는 약제조성무류 | |
| CN104387501A (zh) | 壳聚糖定位酰化缩氨基硫脲类衍生物及其制备方法 | |
| JPS62209100A (ja) | 生体に有用な性質を持つグロビン及びアセチルグロビンの鉄誘導体、その調製法及び薬学的処方物 | |
| JPH0283400A (ja) | 鉄カゼインの製造方法 | |
| JP5591263B2 (ja) | ミネラル添加と酸処理を用いてメチオニンの溶解度を増加させる方法 | |
| JP3131385B2 (ja) | 易吸収性カルシウムを含有する組成物およびその製造方法 | |
| EP2064958B1 (en) | Method for collecting blood and transforming same into a hydrolyzed protein using slaughter animal blood, such as to obtain hydrolyzed blood protein | |
| OA18236A (en) | A process for producing iron (III) casein Nacetyl-aspartylated complexes and use thereof in pharmaceutical compositions. | |
| RU2191590C1 (ru) | Лечебно-профилактическое средство, обладающее детоксицирующей активностью | |
| KR100513011B1 (ko) | 가용성 칼슘-핵산물질 복합체 및 그 제조방법 | |
| JPH01165377A (ja) | 生物学的に大いに利用可能な形態の鉄分含有蛋白質誘導体およびその製法、ならびにそれらを含有する製薬組成物 | |
| JP4247444B2 (ja) | 肝臓機能低下抑制用組成物 | |
| JP3437358B2 (ja) | ミネラル補強用組成物及びその製造方法 | |
| JP2009522286A (ja) | 新規なフィチンクエン酸塩化合物および該化合物の製造方法 | |
| CN109851683B (zh) | 一种金属配合物、一种金属配合物的制备方法和应用 | |
| JP3853816B2 (ja) | カキ肉エキスの製造方法及びカキ肉エキス | |
| CN110467550A (zh) | 一种牛磺酸螯合钙的制备方法 | |
| JPS63276460A (ja) | 鉄高含有血粉及びその製造法 | |
| RU2377929C1 (ru) | Способ получения пищевой добавки цитрата аммония-железа (iii) зеленого | |
| UA26079U (en) | Method for the preparation of polymicroelement medical product from sea-water | |
| JPH06239754A (ja) | 関節リュウマチ剤 |